Form 4: Fennec Pharmaceuticals COO Adrian Haigh Executes Option Exercises and Share Disposals Under 10b5-1 Plan
SEC Form 4 Filing
Adrian Haigh, COO of Fennec Pharmaceuticals, executed option exercises and subsequent share disposals under a pre-arranged 10b5-1 trading plan.
Summary
- On April 19, 2024, Adrian Haigh, the Chief Operating Officer of Fennec Pharmaceuticals, exercised options to acquire 22,222 common shares at a price of $2.31 per share.
- These shares were then disposed of on the same day at a price of $9.335 per share.
- On April 22, 2024, Haigh exercised options to acquire 22,223 common shares at $2.31 per share.
- These shares were then disposed of on the same day at a price of $9.316 per share.
- Both the acquisition and disposal of shares were conducted under a pre-existing 10b5-1 trading plan established on August 17, 2023.
- Following these transactions, Haigh directly owns 360,246 options.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing insider transactions. It doesn't convey any explicit positive or negative sentiment about the company's performance or prospects.
Industry Context
This filing is a routine disclosure of insider transactions and doesn't necessarily indicate a change in the company's outlook or strategy. It reflects the COO's personal financial decisions within the framework of a pre-arranged trading plan.
Key Dates
| Date | Description |
|---|---|
| 04/25/2014 | Original date of option grant. |
| 08/17/2023 | Date of 10b5-1 plan adoption. |
| 04/19/2024 | Date of first option exercise and share disposal. |
| 04/22/2024 | Date of second option exercise and share disposal. |
| 04/25/2024 | Expiration date of options exercised. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.